1. Introduction
===============

Metabolic Syndrome (MetS), known also as Met Syn or Syndrome X, is a complex metabolic disorder which was at first introduced by Hanefeld and Leonhardt and later defined by Dr. Reaven from Stanford University ([@b1-epj-09-5402], [@b2-epj-09-5402]). This syndrome includes obesity, dyslipidemia (low HDL-c and hypertriglyceridemia), hypertension and impaired glucose tolerance, which any three of these criteria constitute diagnosis of MetS and its simultaneous occurrence is more probable than each one per se ([@b1-epj-09-5402]--[@b3-epj-09-5402]). As insulin resistance is an underlying cause of the other risk factors, especially type 2 diabetes and CVD, MetS is also called "insulin resistance syndrome" ([@b4-epj-09-5402]). There are several definitions for MetS; the most commonly used definitions for MetS are those provided by the World Health Organization (WHO), the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III), the International Diabetes Federation (IDF), and the Joint Interim Societies (JIS) ([@b5-epj-09-5402]). Although there are a number of different definitions for MES by various health organizations, the basic components remain constant and include hypertension (HTN), abdominal obesity, glucose intolerance or diabetes, and atherogenic dyslipidemia ([@b6-epj-09-5402]). MetS has deleterious effects and its component increase the chance of cardiovascular diseases (CVD), diabetes, and all-cause mortality ([@b3-epj-09-5402]--[@b6-epj-09-5402]). CVD mortality is significantly higher in MetS patients ([@b7-epj-09-5402], [@b8-epj-09-5402]). Because of the relationship between this syndrome, diabetes, and CVD and its high prevalence, MetS has been considered by most researchers ([@b7-epj-09-5402]--[@b9-epj-09-5402]). The Framingham study showed that MetS alone is a predictor of nearly 25% of CVD new cases ([@b3-epj-09-5402]). In the last two decades, CVD mortality has increased 20 to 45% which one of its underlying reasons was MetS ([@b10-epj-09-5402]) so that it increases total mortality from cardiovascular disease by 1.5-fold and risk for cardiovascular death by 2.5-fold ([@b3-epj-09-5402],[@b7-epj-09-5402]--[@b10-epj-09-5402]). In addition, this syndrome increases the risk of diabetes mellitus 3 times ([@b10-epj-09-5402]). It seems that various factors, including ethnic predisposition, gender, age, race, cultural and lifestyle habits, stress, sedentary behavior, poor diet and socioeconomic status of a society's members affect the prevalence of MetS; thus, its prevalence has large variations in different societies ([@b11-epj-09-5402]--[@b14-epj-09-5402]). The incidence of chronic diseases and MetS in developing countries is more than in developed societies ([@b15-epj-09-5402]). One study in metropolitan Tehran, estimated that the MetS prevalence in the adult population was more than 30% ([@b16-epj-09-5402]). The nationwide prevalence of MetS in the adult population is reported to be 35.6% based on ATP III criteria, which is higher than in developed countries such as the United States ([@b17-epj-09-5402], [@b18-epj-09-5402]). Therefore, MetS is now an emerging health problem at public and individual levels. Strategies and programs for primary prevention of non-communicable diseases emphasize appropriate evaluation and management of risk factors ([@b19-epj-09-5402]), so determining the magnitude of MetS in various populations highlights the need for preventive and management strategies, and enables healthcare services planning. There are many different studies with various populations about the prevalence of MetS in Iran. So, it is very important to have an overall estimation of MetS prevalence by synthesizing available studies; also, understanding the breadth and quality of conducted studies is critical. Recently, one meta-analysis of 28 observational studies was conducted on this topic in Iran ([@b5-epj-09-5402]). Although this review estimated the prevalence of MetS in the adult population, the authors did not perform a meta-analysis among children and adolescents. It seems that CVD risk factors coexist in children similarly to adults. On the other hand, although atherosclerotic disorders are more prevalent in adults, it begins in younger ages ([@b1-epj-09-5402]). So MetS diagnosis among children and adolescents has a significant role in diabetes and CVD prevention ([@b10-epj-09-5402]). Thus we conducted a meta-analysis among children and adolescents. Also, in a recent meta-analysis, the prevalence of various components of the metabolic syndrome had not been definitively determined ([@b5-epj-09-5402]). Furthermore, since the publication of this meta-analysis, further studies have been published on this topic with clinically important results that have not yet been effectively summarized. In order to authenticate studies, performing an updated meta-analysis seems to be necessary. Thus, the main purpose of the present meta-analysis was providing an overall summary measure of prevalence rate of MetS and its components, in Iran.

2. Material and Methods
=======================

The present systematic review/meta-analysis which was performed in 2016--2017 sought to identify papers published on metabolic syndrome prevalence in Iran and included different parts such as problem definition, data collection, analysis, and interpretation of results.

2.1. Search strategy
--------------------

We performed a literature search in English databases; PubMed/Medline, Scopus, and Web of Science from January, 2000 through October, 2016 using a number of keywords. Searching was done in a systematic way using keywords metabolic syndrome, dysmetabolic syndrome, cardiovascular syndrome, and insulin resistance syndrome, prevalence and Iran,. The logical operator AND was used to combine the words together. All probable combinations of the Farsi equivalents of these words were searched for in these Persian databases: Iranmedex, Magiran, SID, and Irandoc. All related trials that were noted in the reference lists of each selected article were verified before inclusion. Bibliographies of retrieved articles were also searched for further references. Additionally, we also hand-searched non-published national surveys and references of selected citations as a further search tool. To decrease bias, two authors did search, selection of papers and extraction of data from articles, independently. In addition, when articles had incomplete data, at least three e-mails were sent to corresponding authors.

2.2. Inclusion and exclusion criteria
-------------------------------------

All papers with the selected keywords in their titles or abstracts were included in the initial list, and other unrelated articles were eliminated. All types of studies, including local and national surveys that reported the prevalence of MetS in Iran were reviewed. We limited the final review to studies with random sampling on healthy children and adolescents who were under 18 years (\<18 years) and/or healthy adults who were aged 18 years and over (≥ 18 years). Studies were excluded if they were conducted on subjects with known health disorders, if they did not provide data that allowed calculation of standard errors for effect estimates, if they were Meta-analyses and systematic reviews, or if they were a duplicate publication of another study. In cases of multiple publications from the same population or cohort, only the largest study was included. The STROBE (strengthening the reporting of observational studies in epidemiology) statement was used for quality control of the studies ([@b20-epj-09-5402]). Non-qualified studies were excluded. When necessary, authors were contacted for additional information. The flowchart of selection of article is illustrated in [Figure 1](#f1-epj-09-5402){ref-type="fig"}.

2.3. Data extraction
--------------------

The following items were extracted from the studies: first author's name, study location, study date, publication date, definition used for MetS, sex groups, mean age, age range, sample size, reported prevalence of MetS extracted by sex (men, women, and total) and age (children and adolescents, adults, and total), reported prevalence of various MetS components \[High Waist circumference (WC), High triglycerides (TG), Low high-density lipoprotein cholesterol (HDL-C), High blood pressure (BP), High fasting blood sugar (FBS)\] according to ATPIII criteria extracted by sex (men, women, and total) and age (children and adolescents, adults, and total), and its 95% confidence interval (CI) concerning the prevalence of MetS components. The abstracts and full articles were independently reviewed by two authors, and data were extracted according to protocol. Any inconsistencies were resolved between researchers by mutual agreement. All data were then admitted into data collection form and entered into Microsoft Excel.

2.4. Data synthesis and Statistical analysis
--------------------------------------------

The main objective of the study was to evaluate the prevalence of MetS and its various components; therefore, its variance was estimated by binominal distributions. Weighting averaging was used to combine prevalence rate in different studies. Each study was given a weight equal to its inverse variance. The heterogeneity between studies was assessed using a Chi-square-based Q test. Wherever the results of studies were heterogeneous, random effects models were used in the meta-analysis. Due to the significant heterogeneity of the studies, the random effects model was applied. The findings are described in forest plots (the point estimations and their 95% CI). The effects of age, sample size and publication date as possible sources of heterogeneity among the study findings was examined by meta-regression. Funnel plots and Egger test were used to examine publication bias. P-values less than 0.05 were considered as significant in heterogeneity tests. Sensitivity analyses were pre-specified. The analyses were conducted with R Software (version 3.2.1) and STATA (version 10).

3. Results
==========

In the primary search, a list of 562 papers and abstracts yielded by searching, was considered relevant and screened. Of these studies, 267 papers were excluded based on title and abstract evaluation (Of these, 115 were on subjects with diseases, 152 were unrelated) and 295 articles were retained for detailed full-text evaluation. In the next step and after full-text evaluation, we excluded another 225 articles (Of these, 37 did not have random sampling, 121 were duplicated articles, 23 were retrospective and review studies, 1 was Meta-analysis, 43 were excluded because of the same target population and overlapping publication); Finally, 67 local studies and 3 national studies that were published between 2003 and 2016 ([@b1-epj-09-5402], [@b4-epj-09-5402]--[@b6-epj-09-5402], [@b10-epj-09-5402], [@b15-epj-09-5402]--[@b17-epj-09-5402], [@b21-epj-09-5402]--[@b82-epj-09-5402]) were identified for meta-analysis ([Figure 1](#f1-epj-09-5402){ref-type="fig"}). The characteristics and extracted data from these studies are shown in [Table 1](#t1-epj-09-5402){ref-type="table"}.

The total sample sizes of studies using the criteria of ATP III, IDF and JIS were 145,887, 87,071, and 11,081, respectively. Among adults, the sample sizes were 128,464, 84,526, 9,635 and 3,770 based on ATP III, IDF, JIS and AHA definition. Also, the total sample sizes among children and adolescents were 17,423, 2,545, 1,446 and 1,300 using the ATP III, IDF, JIS and De Ferranti criteria ([Table 2](#t2-epj-09-5402){ref-type="table"}). [Table 2](#t2-epj-09-5402){ref-type="table"} presents the pooled estimations MetS prevalence using meta-analysis of data extracted from population-based studies in Iran. Forty-two studies were included for the prevalence calculation based on ATPIII criteria; among these studies, we found 33 reports given according to ATP III among adults and nine reports among children and adolescents. Sixteen of the seventy studies estimated MetS prevalence based on IDF definition which was considered in the statistical analysis; of these studies, 13 reports were based on IDF among adults and three reports were among children and adolescents. Sex studies (five among adults and three among children and adolescents) had reported MetS prevalence based on JIS criteria. Among included studies, we found two reports given according to AHA definition among adults and one report given according to De Ferranti definition among children and adolescents. Among adults, the prevalence of MetS was 29.2% (95% CI: 26.2--32.3%) according to the ATP III, 32.8% (95% CI: 28.4--37.2%) based on the IDF, 43.6% (95% CI: 32.6--54.5%) for JIS, 34.5% (95% CI: 17.8--51.1%) according to the AHA definition and in total (31.6% CI: 29.2--34.1%). As it is shown, the prevalence of MetS measured by JIS has been higher than those measured by other definitions; however, there has been no statistically significant difference ([Figure 2](#f2-epj-09-5402){ref-type="fig"}). Also, we estimated the prevalence of MetS in age groups \[≥18 years of age\] according to sex; the prevalence of MetS was lower in men than in women (24.1% versus 35.4%, respectively) for ATP III, (29.9% versus 36.0%, respectively) according to the IDF, (30.5% versus 37.9%, respectively) based on the AHA criteria and in total (26.9% versus 35.7%, respectively). However, the reverse was true for the JIS definition, which showed a significantly higher (15.2%) prevalence in men than in women (52.5% versus 37.3%, respectively ([Table 2](#t2-epj-09-5402){ref-type="table"}).

Among children and adolescents, the overall estimation of MetS was 9.8% (95% CI: 7.2--12.5%) according to the ATP III, 5.5% (95% CI: 4.6--6.3%) based on the IDF, 15% (95% CI: 13.2--16.8%) for JIS and 17.5% (95% CI: 8.7--26.3%) according to the De Ferranti definition and in total (10.2% CI: 8.0--12.5%) ([Figure 3](#f3-epj-09-5402){ref-type="fig"}). As it is shown in [Figure 3](#f3-epj-09-5402){ref-type="fig"}, the prevalence of MetS measured by various criteria has been different; however, this difference was not statistically significant ([Figure 3](#f3-epj-09-5402){ref-type="fig"}). Also, the prevalence of MetS was greater in boys than in girls (11% versus 7.6%, respectively) based on the ATP III (6.0% versus 3.9%, respectively) for IDF, (30.0% versus 2.0%, respectively) according to the JIS, (19.0% versus 15.5%, respectively) based on the De Ferranti criteria and in total (13.0% versus 7.4%, respectively) ([Table 2](#t2-epj-09-5402){ref-type="table"}). [Table 3](#t3-epj-09-5402){ref-type="table"} shows the pooled estimations of prevalence of various components of the metabolic syndrome according to ATPIII criteria using random effect meta-analysis of data extracted from population-based studies in Iran. Metabolic syndrome components prevalence in age groups \[≥18 years of age\] was as follows: High WC (Waist Circumference) 41% (95% CI: 32--50%), High TG (triglyceride) 43% (95% CI: 38--49%), Low HDL-C (High-density lipoprotein-Cholesterol) 54% (95% CI: 48--61%), High BP (Blood Pressure) 38% (95% CI: 31--44%) and High FBS (Fasting Blood Sugar) 22% (95% CI: 17--26%). The overall estimations of prevalence of various MetS components in age \[\<18 years of age\] were as follows: High WC 12% (95% CI: 7.0--17%), High TG 34% (95% CI: 19--48%), Low HDL-C 31% (95% CI: 10--52%), High BP 17% (95% CI: 10--24%) and High FBS 9% (95% CI: 6--12%). Having a WC higher than the normal value was more common for adult women than men (59% versus 27%, respectively); whereas among children and adolescents, the frequency of High WC was almost equal in both sexes (11% versus 9%, respectively). Similar changes were also apparent for HDL-C level lower than the normal value; while among the adult population, the prevalence of low HDL-C was much higher in women than in men (60% versus 48%, respectively), among children and adolescents, the rate was almost similar in boys and girls (23% versus 30%, respectively). Among the adult population, hypertriglyceridemia was more prevalent in men than in women (49% versus 41%, respectively); however, this difference was not statistically significant. Having a TG higher than the normal value was almost similar in both sexes among children and adolescents (32% versus 34%, respectively).

The prevalence of abnormal FPG was much higher in men than in women (26% versus 21%, respectively) and in boys than girls (12% versus 8%, respectively); however, there was no statistically significant difference by gender. The same trend was obtained for the prevalence of hypertension, which found High BP to be less prevalent in women than in men (31% versus 38%, respectively) and in boys than girls (16% versus 21%, respectively) ([Table 3](#t3-epj-09-5402){ref-type="table"}). [Table 4](#t4-epj-09-5402){ref-type="table"} shows the meta-regression parameters. Interpretation of meta-regression showed that there was no significant relationship between the prevalence of metabolic syndrome and sample size (p≥0.05); the reason could be related to a larger sample size with more MetS prevalence and vice versa. [Figure 4](#f4-epj-09-5402){ref-type="fig"} presents the Begg's funnel plot of the association between MetS prevalence and year of each published paper in Iran. Regression analysis of this plot indicated no significant asymmetry (p≥0.05) and thus no evidence of bias ([Figure 4](#f4-epj-09-5402){ref-type="fig"}). As the slope of meta-regression line was negative (p=0.251), there was no association between the metabolic syndrome prevalence with year of study in Iran. The results of the meta-regression show that the main source of heterogeneity in findings was the mean age of participants. The metabolic syndrome prevalence in age groups \[\< 18 years of age\] 10.2% (CI: 10.0--19%) and \[≥ 18 years of age\] 31.6% (CI 95%: 29.2--34.1) was estimated. The results show that by each year increase in the mean age of individuals after the age of 18, the prevalence of MetS increased by 0.004% (coefficient: 0.0048792, p = 0.005).

4. Discussion
=============

In the present study, we considered the prevalence of MetS and its components in our systematic search. We limited our analysis to two age groups: children and adolescents who were under 18 years (\<18 years) and/or adults who were aged 18 years and over (≥ 18 years). Our findings indicate that the prevalence of MetS for age groups (\< 18 years of age) was 10.2% (9.8%: ATP III, 5.5%: IDF, 15.0%: JIS, 17.5%: De Ferranti). The present study showed that the prevalence of MetS among children and adolescents in Iran was higher than in many other countries. In a study conducted in eight European countries among children MetS prevalence was 5.5% ([@b83-epj-09-5402]) and in the U.S, the prevalence of MetS among children and adolescents has been reported as 3.1% to 12.7% with different definitions ([@b84-epj-09-5402]). Prevalence rate of MetS among children and adolescents is very much dependent on the various definitions offered. This figure was 8.9% in 8 to 9-year-old Brazilian children by adopting specific criteria for age ([@b85-epj-09-5402]), 6.5% in Mexico using modified ATP III criteria ([@b86-epj-09-5402]), 6.3% in 7--15-year-old children based on IDF criteria in Turkey ([@b87-epj-09-5402]), 4% based on the modified-ATPIII criteria in Tunisia ([@b88-epj-09-5402]), 6.6% using the De Ferranti definition among elementary school children of China ([@b89-epj-09-5402]), 4.2% using modified ATPIII criteria in north India ([@b90-epj-09-5402]) and 16.5% to 18% among school-aged children in Pakistan based on various definitions ([@b91-epj-09-5402]). The absence of a comprehensive and universal definition of MetS in children and adolescents could, to some extent be a factor in the difference between the reported rates of prevalence from the numerous studies throughout the world. It has also been revealed through conducted studies that over time, the prevalence of MetS is increasing in these age groups. Furthermore, recent reports indicate that due to the increasing rate of childhood obesity on a global scale, the prevalence of childhood MetS has substantially increased during childhood and adolescence ([@b92-epj-09-5402], [@b93-epj-09-5402]). It appears that in developing countries including Iran, childhood obesity plays a major role in the high prevalence of pediatric MetS. Furthermore, obesity, particularly in the central (abdominal) region, is now being considered as a key factor in MetS ([@b75-epj-09-5402]). If the occurrence of MetS in children and adolescents is identified early, risk stratification of future cardiovascular events can be performed.

Another finding of this study indicates that the prevalence of MetS is relatively high in the Iranian adult population according to all definitions (31.6% (29.2%: ATP III, 32.8%: IDF, 43.6%: JIS and 34.5%: AHA)). This was according to the population-based studies in different cities of Iran. In another meta-analysis in Iran, prevalence of MetS among adults with 28 eligible studies was 37% (ATPIII: 36.9%, IDF: 34.6%, and JIS: 41.5%) which was almost similar to our findings ([@b5-epj-09-5402]). So, the prevalence of MetS in Iran was expected to be high. These observed prevalence rates are noticeably higher than the estimated prevalence around the world, which is between 20% and 25% ([@b94-epj-09-5402]). A series of studies on the occurrence of the MetS in Europe have been reported to be ≤ 30%, which is lower than the results of the present study ([@b95-epj-09-5402]). The corresponding figure for MetS prevalence was approximately 26.6% in Spain ([@b96-epj-09-5402]), 20% in Italy ([@b97-epj-09-5402]), 27.6% in Portugal ([@b98-epj-09-5402]) and 20.2% in France ([@b99-epj-09-5402]). It was also higher than in the United States (22.9%) ([@b100-epj-09-5402]). Grundy reported that between 20% and 30% of the adult population in most countries have MetS ([@b101-epj-09-5402]). The present study showed that the mean prevalence of MetS in Iran was found to be higher than in many other countries. The reported studies of Asian countries were similar to our findings. The prevalence of the MetS, as reported from several studies in Central in south Asia was 25.9% ([@b102-epj-09-5402]), Asia-China 33.9% ([@b103-epj-09-5402]), India 41.6% ([@b104-epj-09-5402]) and Turkey 36.6% ([@b104-epj-09-5402]), which showed that its prevalence is relatively high in Asia. Asians have an ethnic predisposition to MetS ([@b17-epj-09-5402],[@b105-epj-09-5402]), and it is of special concern for Middle Eastern populations ([@b17-epj-09-5402]). Also, the prevalence of MetS in Iran is much closer to that in North Africa 30% ([@b106-epj-09-5402]) and some Latin American countries such as Colombia 34.8% ([@b107-epj-09-5402]) and Venezuela 35.3% ([@b108-epj-09-5402]). The present systematic review indicated that the metabolic syndrome is more prevalent in Iran. Although genetic factors play a significant role in the syndrome, some reasons such as urbanization and inactivity have resulted in this relatively high prevalence of MetS in Iran. Obesity is the major driver of MetS development and sedentary lifestyle, a high-fat and fast food dietary is one of the other risk factors ([@b109-epj-09-5402]). In a nationwide study of the prevalence of the metabolic syndrome in Iran, greater waist circumference values and lower HDL-C have also been reported in Iranian communities than in Western populations, which supports the idea of an ethnic predisposition of the Iranian community to MetS ([@b17-epj-09-5402]). Furthermore, it has been shown that MetS is highly age-dependent ([@b110-epj-09-5402]), our study confirmed this finding. We found that the prevalence of MetS in age groups (≥18 years of age) was significantly higher than age groups (\<18 years of age) (31.6% versus 10.2%, respectively); also it increased around 0.004% by each year of age increase after the age of 18. In recent years, the population of Iran has been growing older, and this might be one of the reasons for such a high prevalence of MetS in this country. Our findings show that the prevalence of MetS was more prevalent in Iranian women. Evaluation of studies suggests that sex differences in prevalence are more obvious in older ages. This sex difference can be explained by a statistically significant higher prevalence of MetS components in women ([Table 3](#t3-epj-09-5402){ref-type="table"}). The lack of consensus on MetS definitions and the cutoff points used for its components, especially regarding waist circumference, has resulted in these differences. In the most commonly used definitions for MetS, the cut-off point for waist circumference is usually higher for men and lower for women, which may have resulted in a higher prevalence of MetS being measured in women. A growing trend with increasing age in both genders was significant. The relatively high prevalence of MetS is a worldwide phenomenon. This prevalence appears to be increasing because of a parallel rise in the prevalence of obesity. The present study found Low HDL-C and hypertriglyceridemia as the most prevalent components of MetS, and could be related to unhealthy dietary patterns and physical inactivity. It was followed by High TG, High WC, High BP and High FBS. Each component of the metabolic syndrome has shown to increase the risk of cardiovascular disease and diabetes separately. Consequently, health professionals could evaluate and treat all metabolic risk factors without regard to whether a patient meets the criteria for diagnosis of the metabolic syndrome.

5. Limitations
==============

There are important clinical and public health implications in our results; the results will further contribute to the public health burden of CVD. There are also several limitations to our meta-analysis as insufficient available data prevented us from conducting separate analyses in the evaluation of all age groups. Other limitation is the lack of information about nutrition and lifestyle of the participants, which could explain part of the observed high prevalence. Furthermore, some studies associated with prevalence of MetS were not accessible.

6. Conclusions
==============

The present study shows that the prevalence of MetS is high in the Iranian adult population. Also, it has a relatively high prevalence among children and adolescents. Metabolic syndrome is more prevalent in women than in men and increases with age in both sexes. The lack of consensus on MetS definitions has resulted in different reports of its prevalence. The most common component of MetS was Low HDL-C which was followed by High TG, High WC, High BP and High FBS. This study shows that MetS is a public health problem in Iran. Therefore, applying an appropriate screening and treatment system for MetS could prevent many chronic diseases that are costly to society.
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###### 

Characteristics of different investigated studies (T= total, M= male, F=female).

  Ref. no              Study year   Location                                                        Gender   Sample Size   Age group (year)   Age (year); Mean ± SD
  -------------------- ------------ --------------------------------------------------------------- -------- ------------- ------------------ -----------------------
  [@b16-epj-09-5402]   2003         Tehran                                                          Both     10,363        20 ≤               \-
  [@b3-epj-09-5402]    2006         Yazd                                                            Both     1,110         20 -- 74           49 ± 18
  [@b1-epj-09-5402]    2006         Tehran                                                          Both     1,067         3 -- 9             6.6 ± 1.8
  [@b21-epj-09-5402]   2006         Tehran                                                          Both     515           7 -- 11            \-
  [@b22-epj-09-5402]   2006         Tehran                                                          Both     3,036         10 -- 19           \-
  [@b4-epj-09-5402]    2006         Tehran                                                          Both     1,480         25 -- 64           41.2 ± 12.6
  [@b23-epj-09-5402]   2006         Isfehan, Irak, and Najaf-Abad                                   Both     11,974        19 ≤               35.6 ± 3.4
  [@b24-epj-09-5402]   2006         Tehran                                                          Both     3,777         40 ≤               53.7 ± 9.9
  [@b25-epj-09-5402]   2006         Isfehan, Irak, and Najaf-Abad                                   Both     12,600        20 ≤               \-
  [@b26-epj-09-5402]   2007         Tehran                                                          Both     10,368        20 ≤               42.7 ± 15
  [@b27-epj-09-5402]   2007         Boshehr                                                         Both     3,723         25 ≤               \-
  [@b15-epj-09-5402]   2008         Zanjan                                                          Both     507           17 -- 21           \-
  [@b28-epj-09-5402]   2008         Rafsanjan                                                       Female   1,221         14 -- 18           14.34 ± 1.7
  [@b29-epj-09-5402]   2008         Tehran                                                          Both     4,568         20 ≤               42.6 ± 13.6
  [@b30-epj-09-5402]   2008         Esfahan                                                         Both     4,811         6 -- 18            12.7 ± 3.2
  [@b31-epj-09-5402]   2008         Isfehan, Irak, and Najaf-Abad                                   Both     12,514        19 ≤               \-
  [@b10-epj-09-5402]   2009         Fars                                                            Both     1,402         18 -- 90           38.7 ± 14.3
  [@b32-epj-09-5402]   2009         Mashhad                                                         Female   622           15 -- 17           16.4 ± 0.9
  [@b33-epj-09-5402]   2009         Babol                                                           Female   944           30 -- 50           40.2 ± 0.2
  [@b17-epj-09-5402]   2009         All 30 provinces of Iran, national study                        Both     2,966         25 -- 64           41.3 ± 3.81
  [@b34-epj-09-5402]   2009         Esfahan                                                         Female   1,501         16 -- 49           38 ± 8
  [@b35-epj-09-5402]   2009         Kashan                                                          Male     429           18 ≤               \-
  [@b36-epj-09-5402]   2009         Zanjan                                                          Both     2,941         20 ≤               \-
  1,396                                                                                                                                       
  1,545                                                                                                                                       
  [@b37-epj-09-5402]   2010         Tehran                                                          Both     1,523         10 -- 19           14.8 ± 2.8
  708                                                                                                                                         
  815                                                                                                                                         
  [@b38-epj-09-5402]   2010         Tehran                                                          Both     137           60 -- 90           \-
  [@b39-epj-09-5402]   2011         Tehran                                                          Female   486           40 -- 60           49 ± 6
  [@b40-epj-09-5402]   2011         All 30 provinces of Iran, national study                        Both     3,045         25 -- 64           43.59 ± 11.2
  [@b41-epj-09-5402]   2011         Gorgan                                                          Both     450           15 -- 17           16 ± 0.72
  [@b42-epj-09-5402]   2011         All 30 provinces of Iran, national study                        Both     8,733         25 -- 64           \-
  [@b43-epj-09-5402]   2011         Tabriz                                                          Male     76            18 ≤               41.5 ± 0.74
  [@b44-epj-09-5402]   2011         Jahrom                                                          Both     892           30 ≤               \-
  [@b45-epj-09-5402]   2011         Ghazvin, Kermanshah, Golestan, and Hormozgan, multicity study   Female   914           18 -- 45           \-
  [@b46-epj-09-5402]   2012         Tehran                                                          Both     2,548         50 ≤               60.3 ± 7.4
  [@b47-epj-09-5402]   2012         Semnan                                                          Both     3,799         30 -- 70           45.8 ± 10
  [@b6-epj-09-5402]    2012         Zahedan                                                         Both     1,802         19 ≤               35.85 ± 13.81
  [@b48-epj-09-5402]   2012         Gorga                                                           Female   100           40 ≤               54.3 ± 5.26
  [@b49-epj-09-5402]   2012         Babol                                                           Both     933           20 ≤               \-
  [@b50-epj-09-5402]   2012         Kerman                                                          Both     711           15 -- 75           46.52 ± 14.76
  [@b51-epj-09-5402]   2012         West Azerbaijan                                                 Male     12,138        20 -- 69           \-
  [@b52-epj-09-5402]   2012         Ghazvin                                                         Male     192           18 ≤               39.4 ± 1.3
  [@b53-epj-09-5402]   2012         Yazd                                                            Both     200           20 -- 74           48.75 ± 15
  [@b54-epj-09-5402]   2012         Tehran                                                          Both     365           19 ≤               45.7 ± 16.2
  [@b55-epj-09-5402]   2012         Isfehan, Irak, and Najaf-Abad                                   Both     6,323         35 ≤               50.7 ± 11.6
  [@b56-epj-09-5402]   2012         Greater Khorasan province                                       Both     1,194         35 -- 55           \-
  [@b57-epj-09-5402]   2012         Bushehr Port                                                    Female   382           50 -- 83           58.78 ± 7.8
  [@b58-epj-09-5402]   2013         Ahvaz                                                           Both     912           20 ≤               42.27 ± 14
  [@b59-epj-09-5402]   2013         Tehran                                                          Both     223           18 -- 30           \-
  [@b60-epj-09-5402]   2013         Arak                                                            Both     515           18 ≤               \-
  [@b61-epj-09-5402]   2013         Gorgan                                                          Female   160           18 ≤               32.33 ± 7.08
  [@b62-epj-09-5402]   2013         Shiraz                                                          Female   434           40 ≤               58.6 ± 6.7
  [@b63-epj-09-5402]   2013         Tehran                                                          Both     46,665        20 -- 70           40.7 ± 13.9
  [@b64-epj-09-5402]   2013         Qazvin                                                          Both     1,107         20 -- 78           40.8 ± 10.33
  [@b65-epj-09-5402]   2014         Amol                                                            Both     5,826         16 ≤               40.1 ± 0.24
  [@b65-epj-09-5402]   2014         Zanjan                                                          Both     2,243         16 ≤               36.5 ± 0.39
  [@b66-epj-09-5402]   2014         Qazvin                                                          Both     996           24 ≤               42.1 ± 8.5
  [@b67-epj-09-5402]   2014         Ahvaz                                                           Both     2,246         10 -- 19           \-
  [@b68-epj-09-5402]   2014         Tehran                                                          Both     950           20 ≤               46.5 ± 14.4
  [@b69-epj-09-5402]   2014         Kerman                                                          Both     5,332         20 ≤               46.1 ± 5
  [@b70-epj-09-5402]   2015         Tehran                                                          Both     1,446         18 -- 31           14.6 ± 2.2
  [@b71-epj-09-5402]   2015         Shiraz                                                          Both     377           20 -- 86           43.8 ± 11
  [@b72-epj-09-5402]   2015         Qom                                                             Both     1,488         20 ≤               36 ± 7.7
  [@b73-epj-09-5402]   2015         Azerbaijan                                                      Male     10,000        20 -- 74           38.62 ± 9.7
  [@b74-epj-09-5402]   2015         Lorestan                                                        Both     214           18 -- 30           \-
  [@b75-epj-09-5402]   2015         Birjand                                                         Both     1,425         6 -- 11            9.1
  [@b76-epj-09-5402]   2015         Tehran                                                          Both     785           10 -- 19           14.8 ± 2.9
  [@b77-epj-09-5402]   2015         Tehran                                                          Female   264           40 ≤               53.98 ± 5.57
  [@b78-epj-09-5402]   2015         Kerman                                                          Both     5,874         15 -- 75           44.34 ± 16.32
  [@b79-epj-09-5402]   2015         Babolsar                                                        Both     134           18 ≤               39.8 ± 7.28
  [@b80-epj-09-5402]   2016         Shahroud                                                        Both     5,190         40--64             \-
  [@b81-epj-09-5402]   2016         Shahroud                                                        Male     1,018         18 ≤               42.17 ± 10.65
  [@b82-epj-09-5402]   2016         Tehran                                                          Male     234           18 ≤               36 ± 10.3

###### 

The Overall Prevalence of Metabolic Syndrome in the Iranian Adult Population According to Different Criteria and Sex Using Random Effect Meta-Analysis of Data From Population-based Studies

  Criteria                   Age group   Sample size   Prevalence (%)   I^2^ (%)      p-value
  -------------------------- ----------- ------------- ---------------- ------------- -------------
  ATP III                    Adult       128,464       T: 29.2          T: 99.3       T: \< 0.001
  M: 24.1                    M: 98.9     M: \< 0.001                                  
  F: 35.4                    F: 99.0     F: \< 0.001                                  
  Children and adolescents   17,423      T: 9.8        T: 96.8          T: \< 0.001   
  M: 11                      M: 92.6     M: \< 0.001                                  
  F: 7.6                     F: 89.2     F: \< 0.001                                  
  Total                      145,887     T: 25         T: 99.6          T: \< 0.001   
  M: 22                      M:98.9      M: \< 0.001                                  
  F: 30                      F: 99.6     F: \< 0.001                                  
  IDF                        Adult       84,526        T: 32.8          T: 99.3       T: \< 0.001
  M: 29.9                    M: 98.7     M: \< 0.001                                  
  F: 36                      F: 99.2     F: \< 0.001                                  
  Children and adolescents   2,545       T: 5.5        T: 0.00          T: \> 0.001   
  M: 6.0                     M: 54.2     M: \> 0.001                                  
  F: 3.9                     \-          \-                                           
  Total                      87,071      T: 30         T: 99.6          T: \< 0.001   
  M: 26                      M: 99.2     M: \< 0.001                                  
  F: 29                      F: 99.6     F: \< 0.001                                  
  JIS                        Adult       9,635         T: 43.6          T: 99.1       T: \< 0.001
  M: 52.5                                                                             
  F: 37.3                    F: 99.9     F: \< 0.001                                  
  Children and adolescents   1,446       T: 15         T: 0.00          T: 0.00       
  M: 30                      \-          \-                                           
  F: 2.0                     \-          \-                                           
  Total                      11,081      T: 39         T: 99.5          T: \< 0.001   
  M: 41                      M: 97.9     M: \< 0.001                                  
  F: 23                      F: 99.8     F: \< 0.001                                  
  AHA                        Adult       3,770         T: 34.5          T: 98.7       T: \< 0.001
  M: 30.5                    M: 93.0     M: \< 0.001                                  
  F: 37.9                    F: 98.1     F: \< 0.001                                  
  Children and adolescents   \-          \-            \-               \-            
  Total                      \-          \-            \-               \-            
  De Ferranti                Adult       \-            \-               \-            \-
  Children and adolescents   1,300       T: 17.5       T: 96.8          T: \< 0.001   
  M: 19                      M: 92.0     M: \< 0.001                                  
  F: 15.5                    F: 90.5     F: \> 0.001                                  
  Total                      \-          \-            \-               \-            

###### 

Prevalence of various components of the metabolic syndrome (ATPIII criteria) in various age groups based on gender using random effect meta-analysis of data extracted from population-based studies in Iran

  Variable                             Prevalence (%)   I^2^ (%)   p-value
  -------------------------- --------- ---------------- ---------- ----------
  High WC                    Adult     T: 41            T: 99.9    \< 0.001
  M: 27                      M: 99.8   \< 0.001                    
  F: 59                      F: 99.7   \< 0.001                    
  Children and adolescents   T: 12     T: 99.1          \< 0.001   
  M: 11                      M: 97.9   \< 0.001                    
  F: 9                       F: 95.8   \< 0.001                    
  Total                      T: 34     T: 99.9          \< 0.001   
  M: 24                      M: 99.8   \< 0.001                    
  F: 47                      F: 99.9   \< 0.001                    
  High TG                    Adult     T: 43            T: 99.7    \< 0.001
  M: 49                      M: 99.4   \< 0.001                    
  F: 41                      F: 99.0   \< 0.001                    
  Children and adolescents   T: 34     T: 99.8          \< 0.001   
  M: 32                      M: 99.5   \< 0.001                    
  F: 34                      F: 99.5   \< 0.001                    
  Total                      T: 47     T: 99.9          \< 0.001   
  M: 45                      M: 99.6   \< 0.001                    
  F: 39                      F: 99.4   \< 0.001                    
  Low HDL                    Adult     T: 54            T: 99.8    \< 0.001
  M: 48                      M: 99.8   \< 0.001                    
  F: 60                      F: 99.6   \< 0.001                    
  Children and adolescents   T: 31     T: 99.9          \< 0.001   
  M: 23                      M: 99.3   \< 0.001                    
  F: 30                      F: 99.8   \< 0.001                    
  Total                      T: 49     T: 99.9          \< 0.001   
  M: 42                      M: 99.8   \< 0.001                    
  F: 52                      F: 99.8   \< 0.001                    
  High BP                    Adult     T: 38            T: 99.8    \< 0.001
  M: 38                      M: 99.8   \< 0.001                    
  F: 31                      F: 99.6   \< 0.001                    
  Children and adolescents   T: 17     T: 99.3          \< 0.001   
  M: 21                      M: 98.2   \< 0.001                    
  F: 16                      F: 98.5   \< 0.001                    
  Total                      T: 52     T: 99.8          \< 0.001   
  M: 33                      M: 99.8   \< 0.001                    
  F: 34                      F: 99.8   \< 0.001                    
  High FBS                   Adult     T: 22            T: 99.8    \< 0.001
  M: 26                      M: 99.8   \< 0.001                    
  F: 21                      F: 99.5   \< 0.001                    
  Children and adolescents   T: 9.0    T: 98.9          \< 0.001   
  M: 12                      M: 98.5   \< 0.001                    
  F: 8.0                     F: 97.8   \< 0.001                    
  Total                      T: 28     T: 99.5          \< 0.001   
  M: 23                      M: 99.8   \< 0.001                    
  F: 18                      F: 99.5   \< 0.001                    

###### 

Source of heterogeneity by multivariate meta-regression analysis

  Factors          Coefficient   Standard error   *P*
  ---------------- ------------- ---------------- ---------
  Published year   5.465677      3.614012         0.136
  Sample size      1.305741      0.87             0.84
  Mean age         0.0048792     0.02156          *0.005*
